Hee_老虎社区_美港股上老虎

chefbean
2021-10-27

Hee

Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial

ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from A

Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":855982746,"tweetId":"855982746","gmtCreate":1635324859616,"gmtModify":1635324859616,"author":{"id":3554935180693279,"idStr":"3554935180693279","authorId":3554935180693279,"authorIdStr":"3554935180693279","name":"chefbean","avatar":"https://static.tigerbbs.com/75bcdd1d22221ef3b8f10c64b73ea420","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hee</p></body></html>","htmlText":"<html><head></head><body><p>Hee</p></body></html>","text":"Hee","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/855982746","repostId":1137943402,"repostType":4,"repost":{"id":"1137943402","kind":"news","pubTimestamp":1635324699,"share":"https://www.laohu8.com/m/news/1137943402?lang=&edition=full","pubTime":"2021-10-27 16:51","market":"us","language":"en","title":"Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1137943402","media":"seekingalpha","summary":"ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from A","content":"<ul>\n <li>ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial.</li>\n <li>The difference in estimated glomerular filtration rate (eGFR) between the candidate and placebo was not statistically significant.</li>\n <li>An analysis of only those who completed the trial showed that that those in the ANG-3777 arm had a 12-month eGFR of 57.1mL/min/1.73m2&nbsp;versus 52.2mL/min/1.73m2&nbsp;for placebo. The company said this is \"potentially indicative of biologic activity.\"</li>\n <li>Angion said it had $100M in cash as of Sept. 30.</li>\n <li>In June, Angionabandoned pursuing ANG-3777 as a COVID-19 therapy.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-27 16:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3758498-angion-shares-drop-55-as-kidney-transplant-drug-misses-endpoint-in-late-stage-trial><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial.\n...</p>\n\n<a href=\"https://seekingalpha.com/news/3758498-angion-shares-drop-55-as-kidney-transplant-drug-misses-endpoint-in-late-stage-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3758498-angion-shares-drop-55-as-kidney-transplant-drug-misses-endpoint-in-late-stage-trial","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1137943402","content_text":"ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial.\nThe difference in estimated glomerular filtration rate (eGFR) between the candidate and placebo was not statistically significant.\nAn analysis of only those who completed the trial showed that that those in the ANG-3777 arm had a 12-month eGFR of 57.1mL/min/1.73m2 versus 52.2mL/min/1.73m2 for placebo. The company said this is \"potentially indicative of biologic activity.\"\nAngion said it had $100M in cash as of Sept. 30.\nIn June, Angionabandoned pursuing ANG-3777 as a COVID-19 therapy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":749,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}